Corbus Pharmaceuticals Holdings, Inc.
CRBP$428M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNORWOOD28 employees
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Nov 1, 2026
33wMarket Overview
Stock performance and key metrics
CRBP News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Lenabasum 5 mg
Dermatomyositis
Lenabasum 20 mg
Cystic Fibrosis
JBT-101 (lenabasum)
Cystic Fibrosis
CRB-601 monoclonal antibody
Solid Tumor
CRB-701
Solid Tumor, Adult
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lenabasum 5 mg | Phase 3 | Dermatomyositis | - | - |
Lenabasum 20 mg | Phase 3 | Cystic Fibrosis | - | - |
JBT-101 (lenabasum) | Phase 2 | Cystic Fibrosis | - | - |
CRB-601 monoclonal antibody | Phase 2 | Solid Tumor | - | - |
CRB-701 | Phase 2 | Solid Tumor, Adult | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply